Far-UVC at home, today
Flagged as theatre
A promising, unproven technology. The reference review, after nearly two years of work, lists real-world effectiveness evidence among its pending research priorities: that is, it does not exist yet.
- Level
- Personal
- Cost
- High cost
- Effort
- Hours
- Evidence
- Speculative
What it does not solve
Nothing verifiable yet. Its effectiveness outside the lab, its photobiological safety for skin and eyes, and ozone generation with its mitigation strategies all remain open. As an institutional research line it is legitimate and worth funding; as a household purchase it runs ahead of the evidence, and displaces money that would do more in a fit-tested respirator.
It works if at some point the evidence that is missing today appears. It is only fair to the technology: the idea is a serious one and its institutional line of research is legitimate.
It does not work if you buy it today expecting protection. The “Blueprint for Far-UVCFar-UVCVery short-wavelength ultraviolet light being studied as a way to inactivate viruses and bacteria floating in the air of occupied spaces.For exampleLike an air purifier that, instead of filtering, uses light to disable the microbes floating in the room.”, from June 2025 and the fruit of almost two years of review, examines effectiveness at inactivating pathogens within safe limits of human exposure, photobiological safety for skin and eyes, and ozone generation. What is decisive is where it places real-world effectiveness evidence: among its outstanding research priorities [152]Blueprint for Far-UVCView source ↗. A technology whose effectiveness is still an open question is not a household purchase, it is a line of R&D.
Evidence. Speculative for individual use. The empirical base is only just forming: in 2026 a non-randomised controlled phase II trial was published, at six months, in long-term care facilities [614]The potential effectiveness of far-UVC (222 nm) in preventing infections in long-term care facilities: a six-month nonrandomized controlled phase II trialView source ↗. It is exactly the kind of study that has to accumulate before recommending something to a person, and one alone is not enough.
Cost. High, and with a concrete opportunity cost: the same money goes much further on a reusable respirator with a fit test, which is the best-founded individual recommendation in the biological block.
What it does NOT solve. Nothing verifiable yet. Anyone selling it to you today as personal protection is getting ahead of the evidence, and any site that recommends it is inventing a consensus that its own reference source does not hold.
Does not work if…
- Catastrophe through misuse · Does not work
It is the only branch where it could eventually help, which is why precision matters: buying it today funds a hypothesis rather than acquiring protection.
- AI as normal technology · Does not work
- Gradual disempowerment · Does not work
Risks it addresses
See in the protection matrix →Report a mistake in this entry →
Sources
- [152] Blueprint for Far-UVC · Blueprint Biosecurity 2025
- [614] The potential effectiveness of far-UVC (222 nm) in preventing infections in long-term care facilities: a six-month nonrandomized controlled phase II trial · Antimicrobial Stewardship & Healthcare Epidemiology 2026